MAXIMILIAN AUTHERITH MD, LAURENZ HAUPTMANN MD, SOPHIA KOSCHATKO MD, CHARLOTTE JANTSCH MD, CHRISTINA KRONBERGER MD, MICHAEL POLEDNICZEK MD, KSENIYA HALAVINA MD, CAGLAYAN DEMIREL MD, PhD, ROBIN RISTL PhD, FRANZ DUCA MD, PhD, ANDREAS KAMMERLANDER MD, PhD, MAZEN HANNA MD, MARIANNA FONTANA MD, PhD, MATHEW MAURER MD, PHILIPP E. BARTKO MD, PhD, CHRISTIAN NITSCHE MD, PhD
{"title":"Amyloid-Specific Medication in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Cardiovascular Outcome trials","authors":"MAXIMILIAN AUTHERITH MD, LAURENZ HAUPTMANN MD, SOPHIA KOSCHATKO MD, CHARLOTTE JANTSCH MD, CHRISTINA KRONBERGER MD, MICHAEL POLEDNICZEK MD, KSENIYA HALAVINA MD, CAGLAYAN DEMIREL MD, PhD, ROBIN RISTL PhD, FRANZ DUCA MD, PhD, ANDREAS KAMMERLANDER MD, PhD, MAZEN HANNA MD, MARIANNA FONTANA MD, PhD, MATHEW MAURER MD, PHILIPP E. BARTKO MD, PhD, CHRISTIAN NITSCHE MD, PhD","doi":"10.1016/j.cardfail.2025.08.002","DOIUrl":"10.1016/j.cardfail.2025.08.002","url":null,"abstract":"<div><h3>Background</h3><div>The introduction of disease-specific medication has revolutionized the management of transthyretin-associated cardiomyopathy (ATTR-CM). However, dedicated trials included different patient populations, primary endpoints, and follow-up periods, rendering study comparison challenging. This systematic review and meta-analysis aimed to harmonize data from all phase 3 placebo-controlled drug trials in ATTR-CM to elucidate the magnitude and timing of treatment efficacy of ATTR-specific medication.</div></div><div><h3>Methods</h3><div>We searched PubMed and Embase for trials published up to February 23, 2025 (PROSPERO: CRD42025645376). Efficacy outcomes included all-cause death, cardiovascular (CV) events, change in 6-minute walk distance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and Kansas City Cardiomyopathy Questionnaire Overall Score. Outcome metrics were pooled across trials using inverse-variance weighting and a random-effects model.</div></div><div><h3>Results</h3><div>We included data from 4 identified trials (ATTR-ACT, ATTRibute, APOLLO-B, and HELIOS-B) and 2086 patients. Baseline risk profiles differed substantially, highlighted by a decrease in NT-proBNP and estimated glomerular filtration rate levels from earlier to later trials, likely resulting in different death rates of the respective placebo groups. At 12 months, ATTR-specific medication showed a trend toward less decline in 6-minute walk distance (least squares mean difference: 12.9 meters; 95% confidence interval [CI] −4.1 to 29.8) and was associated with a significantly blunted decline in Kansas City Cardiomyopathy Questionnaire Overall Score (least squares mean difference: 4.7 points; 95% CI 2.3−7.0) and NT-proBNP (geometric mean fold ratio 0.80; 95% CI 0.74−0.85) compared with placebo. These effects are consolidated with continued treatment. At 12-months, ATTR-specific medication did not improve all-cause mortality (OR 1.00; 95% CI 0.69−1.44) compared with placebo. Conversely, over the maximum follow-up period and at 30 months, respectively, ATTR-specific medication reduced the risk of all-cause mortality by 28% (HR 0.72; 95% CI 0.59−0.87) and for CV events by 42% (OR 0.58; 95%CI 0.47−0.73).</div></div><div><h3>Conclusions</h3><div>ATTR-specific medication exhibits early salutary effects on blood biomarkers, functional capacity and quality of life. These effects translate into reductions in CV events and all-cause mortality after continued treatment.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 10","pages":"Pages 1742-1750"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. LUISE HOLZHAUSER MD, JENNA SKOWRONSKI, MARYJANE FARR MD, MSc.
{"title":"Increased Federal Oversight of Donation After Circulatory Death Heart Transplant: Time for a Pause?","authors":"H. LUISE HOLZHAUSER MD, JENNA SKOWRONSKI, MARYJANE FARR MD, MSc.","doi":"10.1016/j.cardfail.2026.02.013","DOIUrl":"10.1016/j.cardfail.2026.02.013","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 10","pages":"Pages 1812-1815"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
GABRIELLE SCHWAB MD, TIFFANY BRAZILE MD, JAMES P. MACNAMARA MD, DENIS J. WAKEHAM PhD, MICHAEL G. LEAHY PhD, ANDREW R. TOMLINSON MD, TONY G. BABB PhD, BRYCE N. BALMAIN PhD, BENJAMIN D. LEVINE MD, SATYAM SARMA MD
{"title":"Fat Distribution and Postural Changes in Pulmonary Capillary Wedge Pressure in Patients With Obesity and Heart Failure With Preserved Ejection Fraction","authors":"GABRIELLE SCHWAB MD, TIFFANY BRAZILE MD, JAMES P. MACNAMARA MD, DENIS J. WAKEHAM PhD, MICHAEL G. LEAHY PhD, ANDREW R. TOMLINSON MD, TONY G. BABB PhD, BRYCE N. BALMAIN PhD, BENJAMIN D. LEVINE MD, SATYAM SARMA MD","doi":"10.1016/j.cardfail.2026.03.029","DOIUrl":"10.1016/j.cardfail.2026.03.029","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 10","pages":"Pages 1842-1844"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implications of urinary albumin-to-creatinine ratio for subsequent kidney function decline and kidney-related outcomes in patients hospitalized for worsening heart failure: Insights from the JROADHF-NEXT registry.","authors":"Yuka Akama, Yu Suresvar Singh, Taisuke Nakade, Yudai Fujimoto, Tomomi Ide, Keisuke Kida, Shouji Matsushima, Nobuyuki Enzan, Masataka Ikeda, Takeshi Kitai, Tatsunori Taniguchi, Takahiro Okumura, Takeshi Tohyama, Hiroyuki Tsutsui, Toshiharu Ninomiya, Tohru Minamino, Jozine M Ter Maaten, Kevin Damman, Adriaan A Voors, Yuya Matsue","doi":"10.1016/j.cardfail.2026.09.033","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.033","url":null,"abstract":"<p><strong>Background: </strong>Albuminuria is a well-established marker of kidney damage. However, its association with subsequent kidney function and outcomes in patients with heart failure remains unclear.</p><p><strong>Methods: </strong>We utilized data from JROADHF-NEXT, a prospective, nationwide registry enrolling patients hospitalized for heart failure. Urinary albumin-to-creatinine ratio (UACR) was measured at discharge, and patients were categorized as A1 (<30 mg/gCr), A2 (30-300 mg/gCr), or A3 (>300 mg/gCr). Outcomes of interest were 2-year all-cause mortality and a composite kidney-related endpoint including kidney-related death, initiation of maintenance dialysis, a ≥40% decline in estimated glomerular filtration rate (eGFR) at 1-year, or progression to kidney failure.</p><p><strong>Results: </strong>Among 3,107 patients, a total of 695 (22.4%) and 361 (11.6%) patients were categorized as A2 and A3, respectively. Higher UACR categories were associated with a greater decline in eGFR from discharge to 1 year (A1: -2.4±0.3; A2: -4.2±0.5; A3: -5.1±0.7 mL/min/1.73 m<sup>2</sup>, P < 0.001). The composite kidney-related endpoint occurred in 195 patients (6.3%), with higher risk in A2 (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.27-2.61; P = 0.001) and A3 (OR 3.69; 95% CI 2.48-5.44; P < 0.001) compared to A1. Higher UACR categories were independently associated with increased mortality (A2 vs A1, Hazard ratio [HR] 1.37; 95% CI 1.12-1.67; P = 0.002; A3 vs A1, HR 1.45; 95% CI 1.12-1.87; P = 0.005).</p><p><strong>Conclusions: </strong>Albuminuria measured at discharge was independently associated with subsequent kidney function decline, adverse kidney-related outcomes, and increased mortality.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to: \"Beyond HFpEF Mimics: Translating Trial Evidence Into Clinical Practice\".","authors":"Milton Packer, Barry A Borlaug","doi":"10.1016/j.cardfail.2026.09.019","DOIUrl":"10.1016/j.cardfail.2026.09.019","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"JCF In Case You Missed It! Summary of European Society of Cardiology (ESC) Congress 2026.","authors":"Diana De Oliveira-Gomes, Alexander Hajduczok","doi":"10.1016/j.cardfail.2026.09.012","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.012","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Priyesh A Patel, Mark H Drazner, Austin L Seals, Christopher Chien, Andrew Phillips, Conrad Macon, Nosheen Reza, Sean Pinney, Eiran Z Gorodeski, Olivia Gilbert
{"title":"A National Survey of Compensation and Productivity in Advanced Heart Failure and Transplant Cardiology.","authors":"Priyesh A Patel, Mark H Drazner, Austin L Seals, Christopher Chien, Andrew Phillips, Conrad Macon, Nosheen Reza, Sean Pinney, Eiran Z Gorodeski, Olivia Gilbert","doi":"10.1016/j.cardfail.2026.09.011","DOIUrl":"10.1016/j.cardfail.2026.09.011","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}